FIRST

Samenvatting

A randomized, double-blind, phase 3 comparison of Platinum-based therapy with tsr042 and niraparib Versus standard of care platinum-based therapy as first-line treatment of stage iii or iv nonmucinous epithelial ovarian cancer.

Primair eindpunt

PFS

Aantal benodigde patiënten

720-960 in 1:1:2 ratio gerandomiseerd

Contactgegevens

An Reyners

Deelnemende centra: UMCU, Erasmus MC, UMCG, AMC